Alisha Charlton Sells 2,300 Shares of Pro-Dex (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) CFO Alisha Charlton sold 2,300 shares of Pro-Dex stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $61.30, for a total value of $140,990.00. Following the sale, the chief financial officer directly owned 21,870 shares of the company’s stock, valued at approximately $1,340,631. This trade represents a 9.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Pro-Dex Price Performance

Shares of PDEX stock opened at $62.81 on Friday. Pro-Dex, Inc. has a twelve month low of $23.47 and a twelve month high of $77.00. The company has a current ratio of 4.10, a quick ratio of 2.45 and a debt-to-equity ratio of 0.28. The stock has a fifty day simple moving average of $62.42 and a two-hundred day simple moving average of $57.71. The stock has a market capitalization of $200.99 million, a price-to-earnings ratio of 15.21 and a beta of 0.06.

Pro-Dex (NASDAQ:PDEX) last announced its quarterly earnings results on Thursday, September 3rd. The medical instruments supplier reported $0.87 EPS for the quarter, beating the consensus estimate of $0.67 by $0.20. The firm had revenue of $20.40 million for the quarter, compared to analyst estimates of $19.20 million. Pro-Dex had a return on equity of 25.13% and a net margin of 17.62%. On average, analysts predict that Pro-Dex, Inc. will post 2.78 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on PDEX. Wall Street Zen upgraded shares of Pro-Dex from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Zacks Research upgraded shares of Pro-Dex to a “hold” rating in a research note on Tuesday, May 19th. Weiss Ratings raised shares of Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, September 4th. Finally, Ascendiant Capital Markets boosted their price objective on shares of Pro-Dex from $70.00 to $74.00 and gave the stock a “buy” rating in a research note on Friday. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $74.00.

Institutional Trading of Pro-Dex

Several hedge funds have recently modified their holdings of PDEX. Los Angeles Capital Management LLC bought a new stake in shares of Pro-Dex in the 4th quarter valued at about $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Pro-Dex during the 2nd quarter worth approximately $50,000. Bank of America Corp DE raised its stake in shares of Pro-Dex by 173.3% during the 2nd quarter. Bank of America Corp DE now owns 1,692 shares of the medical instruments supplier’s stock worth $74,000 after acquiring an additional 1,073 shares in the last quarter. Wells Fargo & Company MN lifted its position in Pro-Dex by 65.4% during the fourth quarter. Wells Fargo & Company MN now owns 2,314 shares of the medical instruments supplier’s stock valued at $89,000 after acquiring an additional 915 shares during the last quarter. Finally, California State Teachers Retirement System purchased a new stake in Pro-Dex during the second quarter valued at approximately $99,000. 15.28% of the stock is owned by hedge funds and other institutional investors.

About Pro-Dex

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.